title: New combinations with epirubicin in advanced breast cancer.
abstract: Several trials have shown that anthracyclines and taxanes can be combined to achieve response rates ranging from 70% to 90%, with complete responses ranging from 19% to 41%. In an attempt to increase the activity while maintaining tolerability, gemcitabine (Gemzar) was added to the epirubicin (Ellence)/paclitaxel (Taxol) regimen. Among 36 metastatic breast cancer patients treated with this new combination, the overall response rate was 92%, including 31% with a complete response. Another attempt to improve the outcome of metastatic breast cancer patients involves a phase III multicentric randomized trial (MANTA-1) to evaluate if paclitaxel maintenance therapy after anthracycline/taxane combination therapy can improve time to progression and overall survival. Although anthracyclines are more frequently used in the adjuvant setting, it is important for the clinicians to know whether this class of drugs can be used again for those patients who develop metastatic disease. An analysis of 312 patients treated with epirubicin containing regimens as first-line treatment for metastatic disease shows that epirubicin-based regimens are active in patients already exposed to anthracyclines in the adjuvant setting, and that the risk of cardiac toxicity is low up to a cumulative epirubicin dose of 990 mg/m2.
authors.affiliation: Division of Medical Oncology, St. Chiara University Hospital, Pisa, Italy. pconte@do.med.unipi.it
authors.forename: P
authors.initials: P
authors.lastname: Conte
authors.forename: A
authors.initials: A
authors.lastname: Gennari
authors.forename: E
authors.initials: E
authors.lastname: Landucci
authors.forename: V
authors.initials: V
authors.lastname: Guarneri
authors.forename: S
authors.initials: S
authors.lastname: Donati
authors.forename: B
authors.initials: B
authors.lastname: Salvadori
authors.forename: C
authors.initials: C
authors.lastname: Bengala
authors.forename: C
authors.initials: C
authors.lastname: Orlandini
mesh_terms: D000328:Adult; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000401:mortality; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D015251:Epirubicin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008875:Middle Aged; D017239:Paclitaxel / Q000627:therapeutic use; D015996:Survival Rate; D013997:Time Factors; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D015251:Epirubicin; D017239:Paclitaxel; D000093542:Gemcitabine